Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic,
antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin
alfa activated produced dose-dependent reductions in the levels of markers of coagulation
and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed
whether treatment with drotrecogin alfa activated reduced the rate of death from any
cause among patients with severe sepsis.